12:00 AM
 | 
Aug 27, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Fycompa perampanel: Interim extension study data

Interim data from the open-label Phase III Study 307 extension study in 1,218 patients who completed 1 of the double-blind Phase III Study 304, 305 or 306 trials showed that once-daily perampanel had an acceptable tolerability profile at a median treatment duration of 51.4 weeks, with serious adverse events reported in 13.2% of patients. Eisai also said that reduced seizure frequency and...

Read the full 290 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >